期刊文献+

二代测序技术检测284例结直肠癌突变基因特征分析

Analysis of mutant gene characteristics in 284 cases of colorectal cancer detected by next-generation sequencing technology
下载PDF
导出
摘要 目的:探讨结直肠癌患者基因突变与临床病理特征关系及对生存期的影响。方法:二代测序技术检测基因突变状态,统计学方法分析基因突变与临床病理特征关系及对生存期的影响。结果:结直肠癌患者基因突变率为84.51%,其中KRAS以G12D、G12V和G13D突变为主,TP53常见突变为R273H和R248W,PIK3CA以E545K、E542K和H1047R突变为主,APC常见突变为T1556Nfs^(*)3和R1450^(*),BRAF突变类型为V600E、K601E和G469A。基因共突变率为64.79%,KRAS与TP53共突变最常见。男性及淋巴结转移者更易发生KRAS突变,肿瘤中-高期分化者易发生TP53突变,右半结肠、肿瘤溃疡型及中-高期分化者易发生PIK3CA突变。左半结肠易发生APC突变,而右半结肠易发生BRAF突变。KRAS和BRAF野生型比突变型患者可获得更长的生存期。结论:结直肠癌中突变频率较高的驱动基因分别为KRAS、TP53、PIK3CA、APC和BRAF,在不同临床病理特征中它们的突变率存在差异性,KRAS和BRAF突变型对患者生存期具有一定影响。 Objective:To explore the relationship between colorectal cancer patients gene mutation and clinicopathological characteristics,and the effect on survival.Methods:The gene mutation status was detected using next-generation sequencing technology,and the relationship between gene mutation and clinicopathological characteristics as well as the influence on survival was analyzed statistically.Results:The gene mutation rate in colorectal cancer patients was 84.51%,KRAS was dominated with G12D,G12V and G13D mutations,TP53 was dominated with R273H and R248W mutations,and PIK3CA was dominated with E545K,E542K and H1047R mutations.The frequent mutations were T1556Nfs~*3 and R1450~* in APC,BRAF was dominated with V600E,K601E and G469A.The gene co-mutation rate was 64.79%,and KRAS paired with TP53 was the commonest.Male and lymphatic metastases were more likely to occur KRAS mutation.TP53 mutation tend to occur in patients with medium-high tumor differentiation.PIK3CA mutations were more likely to occur in the right half colon,ulcerative tumors and medium-high stage differentiation.The left half colon was prone to APC mutation,and the right half colon was prone to BRAF mutation.KRAS and BRAF wild-type patients have a longer survival than mutant ones.Conclusion:The driver genes with high mutation frequency in colorectal cancer were KRAS,TP53,PIK3CA,APC and BRAF,and their mutation rates differ by clinicopathological features.KRAS and BRAF mutation had a certain impact on patient survival.
作者 赵婷婷 刘杰 ZHAO Tingting;LIU Jie(Department of Clinical Laboratory,Yantai Yuhuangding Hospital Affiliated to Qingdao University,Shandong Yantai 264099,China)
出处 《现代肿瘤医学》 CAS 2024年第13期2394-2400,共7页 Journal of Modern Oncology
基金 山东省自然科学基金(编号:ZR2023MH280)。
关键词 结直肠癌 基因突变 二代测序 KRAS colorectal cancer gene mutation next-generation sequencing KRAS
  • 相关文献

参考文献5

二级参考文献67

  • 1Jemal A,Bray F,Center MM,et al. Global cancer statistics[J]. CA Cancer J Clin,2011,61 (2) :69 -90.
  • 2Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012 [ J ]. CA Cancer J Clin,2012,62(2) :10 -29.
  • 3Roper J, Richardson MP, Wanq WV, et al. The dual PI3K/mTOR inhibitor NVP - BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild - type colorectal cancer [J]. PloS One,2011,6(9) :e25132.
  • 4Amado RG, Wolf M, Peeters M, et al. Wild type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer[ J]. J Clin Oncol,2008,26(10) :1626 -1634.
  • 5Bokemeyer C, Kohne C, Rougier P, et al. Cetuximab with chemo- therapy (CT) as first - line treatment for metastatic coloreetal cancer (mCRC) :Analysis of the CRYSTAL and OPUS studies ac- cording to KRAS and BRAF mutation status [J]. J Clin Oncol, 2010,28(15s) :3506.
  • 6Siena S, Sartore - Bianchi A, Di Nicolantonio F, et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor - targeted therapy in metastatic colorectal cancer [ J ]. J Natl Cancer Inst,2009,101 : 1308 - 1324.
  • 7Garrido - Laguna I, Hong DS, Janku F, et al. KRASness and PIK3 CAness in patients with advanced eoloreetal cancer:Outcome after treatment with early - phase trials with targeted pathway in- hibitors [ J ]. PLoS ONE ,2012,7 (5) : e38033.
  • 8Ligresti G, Militello L, Steelman LS, et al. PIK3 CA mutations in hu- man solid tumors:role in sensitivity to various therapeutic approa- ches[J]. Cell Cycle,2009,8(9) :1352 -1358.
  • 9Guo JP, Coppola D, Cheng JQ. IKBKE protein activates Akt inde- pendent of phosphatidylinositol 3 - kinase/PDKl/mTORC2 and the pleckstrin homology domain to sustain malignant transforma- tion[J]. J Biol Chem,2011,286(43) :37389 -37398.
  • 10Oikonomou E, Pintzas A. Cancer genetics of sporadic colorectal eancer:BRAF and PI3KCA mutations, their impact on signaling and novel targeted therapies[ J]. Anticancer Res ,2006,26 (2A) : 1077 - 1084.

共引文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部